According to the study conducted by Sun et al., targeting the STAT3/HOTAIR/EZH2 axis could present a novel therapeutic approach for effectively treating PI3K-activated HNSCC patients with a combination of cisplatin and cetuximab [79]. The gene discussed is EZH2; the disease is head and neck squamous cell carcinoma.